No-Spa is a diastolic drug that reduces pain (painful cramps) in the abdominal cavity and pelvic organs, i.e. in the gastrointestinal tract (stomach and intestines), biliary and urinary tract, and in women also in the reproductive tract.
No-Spa contains the active ingredient drotaverine hydrochloride. This substance is used in the contraction of smooth muscles of both nervous and muscular origin. The relaxing effect of drotaverine does not depend on the type of innervation and the location of smooth muscles (gastrointestinal tract, urogenital system, circulatory system and biliary system).
Soothing muscle contractions associated with diseases of the bile ducts: cholelithiasis, cholecystitis, peritheitis, bile duct inflammation, Vater’s papillitis.
Urinary tract muscle contractions: kidney stones, ureterolithiasis, inflammation of renal pelvis, cystitis, painful urge to urinate.
As supportive therapy, it can be used safely and with the desired effect:
- in contractile states of smooth muscles of the gastrointestinal tract: gastric and duodenal ulcer disease, gastritis, enteritis, colitis, contractile states of the gastric tab and pylorus, irritable colon syndrome, spastic constipation and intestinal distension, pancreatitis.
- in gynecological diseases: dysmenorrhea.
Active substance: Drotaverini hydrochloridum
1 tablet of No-Spa contains 40 mg of drotaverine hydrochloride (Drotaverini hydrochloridum)
Adults: The daily dose of 120 to 240 mg, in 2 – 3 divided doses.
Children: Clinical trials have not been conducted in children.
If it is necessary to use No-Spa 40 mg in children: the daily dose for children aged 6 to 12 years is 80 mg, in 2 divided doses, for children over 12 years: the daily dose is 160 mg, in 2-4 divided doses
Hypersensitivity to the active substance or any of the excipients of the product.
Severe liver, kidney and heart failure.
Second and third degree AV block.
Do not use in children under 6 years of age.
Due to the lactose content, the medicinal product may cause gastrointestinal discomfort in lactose intolerant patients.
The product should not be used in patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
The product should be used with caution in patients with hypotension.
The product should be used with caution in children, as drotaverine has not been studied in this patient group.
Caution should be exercised when using drotaverine in pregnant women.
Drotaverine should not be used during labor.
If you have been diagnosed with an intolerance to some sugars, contact your doctor before taking the drug.
Pregnancy and lactation
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Drotaverine crosses the placenta.
Do not use the drug during childbirth.
At therapeutic doses, orally administered drotaverine has no influence on the ability to drive and use machines.
Patients should be advised that if they feel dizzy they should avoid potentially hazardous activities such as driving or operating machinery.
There are no known cases of overdosage with drotaverine. In the event of overdose, the patient should be carefully monitored and treatment instituted symptomatically.
Interactions with other drugs
Tell the doctor or pharmacist about all the drugs taken by the patient now or recently, as well as about the drugs that the patient is planning to take.
Caution should be exercised with concomitant administration with levodopa (a drug used in Parkinson’s disease) due to the reduction of its anti-parkinsonian effects and the increase in tremors and stiffness.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Rare (may affect up to 1 in 1,000 people):
- allergic reactions (angioedema, hives, rash, itching)
- headache, dizziness, insomnia
- palpitations, decrease in blood pressure
- nausea, constipation.